nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—CYP17A1—breast cancer	0.513	0.782	CbGaD
Metoclopramide—CYP2D6—breast cancer	0.143	0.218	CbGaD
Metoclopramide—CYP2D6—Idarubicin—breast cancer	0.00305	0.414	CbGbCtD
Metoclopramide—HTR4—pituitary gland—breast cancer	0.00163	0.158	CbGeAlD
Metoclopramide—CYP2D6—Vinorelbine—breast cancer	0.00149	0.202	CbGbCtD
Metoclopramide—HTR4—adrenal gland—breast cancer	0.00146	0.141	CbGeAlD
Metoclopramide—CYP2D6—Tamoxifen—breast cancer	0.00135	0.182	CbGbCtD
Metoclopramide—CYP2D6—Vinblastine—breast cancer	0.000919	0.125	CbGbCtD
Metoclopramide—CYP11B2—adrenal gland—breast cancer	0.000821	0.0795	CbGeAlD
Metoclopramide—CYP11B1—adrenal gland—breast cancer	0.000821	0.0795	CbGeAlD
Metoclopramide—CYP11B2—endocrine gland—breast cancer	0.000712	0.069	CbGeAlD
Metoclopramide—CYP11B1—endocrine gland—breast cancer	0.000712	0.069	CbGeAlD
Metoclopramide—Sunitinib—STK11—breast cancer	0.000696	0.0787	CrCbGaD
Metoclopramide—Proparacaine—SCN10A—breast cancer	0.000578	0.0653	CrCbGaD
Metoclopramide—CYP2D6—Doxorubicin—breast cancer	0.000565	0.0765	CbGbCtD
Metoclopramide—Oxybuprocaine—SCN10A—breast cancer	0.000529	0.0598	CrCbGaD
Metoclopramide—CYP17A1—female reproductive system—breast cancer	0.000514	0.0498	CbGeAlD
Metoclopramide—CYP17A1—adrenal gland—breast cancer	0.000502	0.0486	CbGeAlD
Metoclopramide—CYP11B2—lymph node—breast cancer	0.000492	0.0477	CbGeAlD
Metoclopramide—Chloroprocaine—SCN10A—breast cancer	0.000492	0.0556	CrCbGaD
Metoclopramide—Cinchocaine—SCN10A—breast cancer	0.000469	0.053	CrCbGaD
Metoclopramide—Procaine—SCN10A—breast cancer	0.000469	0.053	CrCbGaD
Metoclopramide—CYP17A1—female gonad—breast cancer	0.000468	0.0453	CbGeAlD
Metoclopramide—Sunitinib—CHEK2—breast cancer	0.000449	0.0507	CrCbGaD
Metoclopramide—CYP17A1—endocrine gland—breast cancer	0.000435	0.0421	CbGeAlD
Metoclopramide—Sunitinib—FGFR1—breast cancer	0.000419	0.0473	CrCbGaD
Metoclopramide—Sunitinib—FGFR2—breast cancer	0.000419	0.0473	CrCbGaD
Metoclopramide—Sunitinib—ALK—breast cancer	0.0004	0.0452	CrCbGaD
Metoclopramide—Sunitinib—FLT1—breast cancer	0.0004	0.0452	CrCbGaD
Metoclopramide—Procainamide—DNMT1—breast cancer	0.000391	0.0442	CrCbGaD
Metoclopramide—Sunitinib—CSF1R—breast cancer	0.000379	0.0429	CrCbGaD
Metoclopramide—CHRM1—female reproductive system—breast cancer	0.000306	0.0297	CbGeAlD
Metoclopramide—CYP17A1—lymph node—breast cancer	0.000301	0.0291	CbGeAlD
Metoclopramide—Oxybuprocaine—BCHE—breast cancer	0.000296	0.0335	CrCbGaD
Metoclopramide—Chloroprocaine—BCHE—breast cancer	0.000275	0.0311	CrCbGaD
Metoclopramide—DRD2—pituitary gland—breast cancer	0.00027	0.0261	CbGeAlD
Metoclopramide—Procaine—BCHE—breast cancer	0.000263	0.0297	CrCbGaD
Metoclopramide—Cinchocaine—BCHE—breast cancer	0.000263	0.0297	CrCbGaD
Metoclopramide—CHRM1—endocrine gland—breast cancer	0.000259	0.0251	CbGeAlD
Metoclopramide—Sunitinib—KDR—breast cancer	0.000251	0.0283	CrCbGaD
Metoclopramide—Procainamide—SCN10A—breast cancer	0.000243	0.0274	CrCbGaD
Metoclopramide—Sunitinib—KIT—breast cancer	0.000237	0.0267	CrCbGaD
Metoclopramide—Procainamide—ACHE—breast cancer	0.000231	0.0261	CrCbGaD
Metoclopramide—DRD2—endocrine gland—breast cancer	0.000209	0.0202	CbGeAlD
Metoclopramide—CYP2D6—female reproductive system—breast cancer	0.000148	0.0144	CbGeAlD
Metoclopramide—Leukopenia—Paclitaxel—breast cancer	0.000137	0.00077	CcSEcCtD
Metoclopramide—Rash—Tamoxifen—breast cancer	0.000137	0.000769	CcSEcCtD
Metoclopramide—Hypersensitivity—Vinorelbine—breast cancer	0.000137	0.000769	CcSEcCtD
Metoclopramide—Dermatitis—Tamoxifen—breast cancer	0.000137	0.000769	CcSEcCtD
Metoclopramide—Dyspnoea—Irinotecan—breast cancer	0.000137	0.000767	CcSEcCtD
Metoclopramide—Dyspnoea—Mitoxantrone—breast cancer	0.000137	0.000767	CcSEcCtD
Metoclopramide—Somnolence—Irinotecan—breast cancer	0.000136	0.000765	CcSEcCtD
Metoclopramide—Somnolence—Mitoxantrone—breast cancer	0.000136	0.000765	CcSEcCtD
Metoclopramide—Headache—Tamoxifen—breast cancer	0.000136	0.000764	CcSEcCtD
Metoclopramide—Procainamide—BCHE—breast cancer	0.000136	0.0154	CrCbGaD
Metoclopramide—Palpitations—Paclitaxel—breast cancer	0.000135	0.00076	CcSEcCtD
Metoclopramide—Insomnia—Gemcitabine—breast cancer	0.000135	0.000758	CcSEcCtD
Metoclopramide—CYP2D6—female gonad—breast cancer	0.000135	0.0131	CbGeAlD
Metoclopramide—Asthma—Methotrexate—breast cancer	0.000134	0.000754	CcSEcCtD
Metoclopramide—Rash—Melphalan—breast cancer	0.000134	0.000753	CcSEcCtD
Metoclopramide—Flushing—Capecitabine—breast cancer	0.000134	0.000753	CcSEcCtD
Metoclopramide—Dermatitis—Melphalan—breast cancer	0.000134	0.000753	CcSEcCtD
Metoclopramide—Asthenia—Vinorelbine—breast cancer	0.000133	0.000749	CcSEcCtD
Metoclopramide—Dyspnoea—Gemcitabine—breast cancer	0.000133	0.000748	CcSEcCtD
Metoclopramide—Nausea—Vinblastine—breast cancer	0.000133	0.000746	CcSEcCtD
Metoclopramide—Insomnia—Fluorouracil—breast cancer	0.000133	0.000746	CcSEcCtD
Metoclopramide—Somnolence—Gemcitabine—breast cancer	0.000133	0.000745	CcSEcCtD
Metoclopramide—Convulsion—Paclitaxel—breast cancer	0.000133	0.000745	CcSEcCtD
Metoclopramide—Hypertension—Paclitaxel—breast cancer	0.000132	0.000743	CcSEcCtD
Metoclopramide—Fatigue—Irinotecan—breast cancer	0.000132	0.000742	CcSEcCtD
Metoclopramide—Fatigue—Mitoxantrone—breast cancer	0.000132	0.000742	CcSEcCtD
Metoclopramide—Sunitinib—ABCG2—breast cancer	0.000131	0.0148	CrCbGaD
Metoclopramide—Dyspnoea—Fluorouracil—breast cancer	0.000131	0.000735	CcSEcCtD
Metoclopramide—Rash—Goserelin—breast cancer	0.000131	0.000735	CcSEcCtD
Metoclopramide—Hypersensitivity—Thiotepa—breast cancer	0.000131	0.000734	CcSEcCtD
Metoclopramide—Dermatitis—Goserelin—breast cancer	0.000131	0.000734	CcSEcCtD
Metoclopramide—Somnolence—Fluorouracil—breast cancer	0.00013	0.000733	CcSEcCtD
Metoclopramide—Headache—Goserelin—breast cancer	0.00013	0.00073	CcSEcCtD
Metoclopramide—Anxiety—Paclitaxel—breast cancer	0.00013	0.00073	CcSEcCtD
Metoclopramide—Nausea—Tamoxifen—breast cancer	0.000129	0.000725	CcSEcCtD
Metoclopramide—Fatigue—Gemcitabine—breast cancer	0.000129	0.000723	CcSEcCtD
Metoclopramide—Cisapride—CYP2D6—breast cancer	0.000128	0.0145	CrCbGaD
Metoclopramide—Cardiac arrest—Doxorubicin—breast cancer	0.000128	0.000719	CcSEcCtD
Metoclopramide—Asthenia—Thiotepa—breast cancer	0.000127	0.000715	CcSEcCtD
Metoclopramide—Diarrhoea—Vinorelbine—breast cancer	0.000127	0.000714	CcSEcCtD
Metoclopramide—Nausea—Melphalan—breast cancer	0.000126	0.00071	CcSEcCtD
Metoclopramide—Feeling abnormal—Irinotecan—breast cancer	0.000126	0.000709	CcSEcCtD
Metoclopramide—Feeling abnormal—Mitoxantrone—breast cancer	0.000126	0.000709	CcSEcCtD
Metoclopramide—Confusional state—Paclitaxel—breast cancer	0.000126	0.000708	CcSEcCtD
Metoclopramide—Asthma—Epirubicin—breast cancer	0.000126	0.000706	CcSEcCtD
Metoclopramide—Neutropenia—Methotrexate—breast cancer	0.000126	0.000705	CcSEcCtD
Metoclopramide—CYP2D6—endocrine gland—breast cancer	0.000125	0.0122	CbGeAlD
Metoclopramide—Oedema—Paclitaxel—breast cancer	0.000125	0.000702	CcSEcCtD
Metoclopramide—Muscle spasms—Docetaxel—breast cancer	0.000125	0.000701	CcSEcCtD
Metoclopramide—Erectile dysfunction—Methotrexate—breast cancer	0.000124	0.000695	CcSEcCtD
Metoclopramide—Nausea—Goserelin—breast cancer	0.000123	0.000692	CcSEcCtD
Metoclopramide—Feeling abnormal—Gemcitabine—breast cancer	0.000123	0.000691	CcSEcCtD
Metoclopramide—Dizziness—Vinorelbine—breast cancer	0.000123	0.00069	CcSEcCtD
Metoclopramide—Tachycardia—Paclitaxel—breast cancer	0.000122	0.000685	CcSEcCtD
Metoclopramide—Urticaria—Mitoxantrone—breast cancer	0.000122	0.000684	CcSEcCtD
Metoclopramide—Diarrhoea—Thiotepa—breast cancer	0.000121	0.000682	CcSEcCtD
Metoclopramide—Body temperature increased—Irinotecan—breast cancer	0.000121	0.000681	CcSEcCtD
Metoclopramide—Body temperature increased—Mitoxantrone—breast cancer	0.000121	0.000681	CcSEcCtD
Metoclopramide—Feeling abnormal—Fluorouracil—breast cancer	0.000121	0.000679	CcSEcCtD
Metoclopramide—Muscle spasms—Capecitabine—breast cancer	0.000121	0.000679	CcSEcCtD
Metoclopramide—Drowsiness—Methotrexate—breast cancer	0.00012	0.000673	CcSEcCtD
Metoclopramide—Depression—Methotrexate—breast cancer	0.000119	0.000671	CcSEcCtD
Metoclopramide—Body temperature increased—Gemcitabine—breast cancer	0.000118	0.000663	CcSEcCtD
Metoclopramide—Tremor—Capecitabine—breast cancer	0.000118	0.000661	CcSEcCtD
Metoclopramide—Neutropenia—Epirubicin—breast cancer	0.000117	0.00066	CcSEcCtD
Metoclopramide—Dizziness—Thiotepa—breast cancer	0.000117	0.000659	CcSEcCtD
Metoclopramide—Rash—Vinorelbine—breast cancer	0.000117	0.000658	CcSEcCtD
Metoclopramide—Dermatitis—Vinorelbine—breast cancer	0.000117	0.000658	CcSEcCtD
Metoclopramide—Hypotension—Paclitaxel—breast cancer	0.000117	0.000656	CcSEcCtD
Metoclopramide—Urticaria—Fluorouracil—breast cancer	0.000117	0.000655	CcSEcCtD
Metoclopramide—Headache—Vinorelbine—breast cancer	0.000116	0.000654	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—breast cancer	0.000116	0.000653	CcSEcCtD
Metoclopramide—Leukopenia—Docetaxel—breast cancer	0.000116	0.000653	CcSEcCtD
Metoclopramide—Pollakiuria—Epirubicin—breast cancer	0.000116	0.000652	CcSEcCtD
Metoclopramide—Body temperature increased—Fluorouracil—breast cancer	0.000116	0.000652	CcSEcCtD
Metoclopramide—Palpitations—Docetaxel—breast cancer	0.000115	0.000644	CcSEcCtD
Metoclopramide—Insomnia—Paclitaxel—breast cancer	0.000113	0.000635	CcSEcCtD
Metoclopramide—Hypersensitivity—Irinotecan—breast cancer	0.000113	0.000634	CcSEcCtD
Metoclopramide—Hypersensitivity—Mitoxantrone—breast cancer	0.000113	0.000634	CcSEcCtD
Metoclopramide—Leukopenia—Capecitabine—breast cancer	0.000112	0.000632	CcSEcCtD
Metoclopramide—Convulsion—Docetaxel—breast cancer	0.000112	0.000632	CcSEcCtD
Metoclopramide—Hypertension—Docetaxel—breast cancer	0.000112	0.00063	CcSEcCtD
Metoclopramide—Drowsiness—Epirubicin—breast cancer	0.000112	0.000629	CcSEcCtD
Metoclopramide—Rash—Thiotepa—breast cancer	0.000112	0.000629	CcSEcCtD
Metoclopramide—Dermatitis—Thiotepa—breast cancer	0.000112	0.000628	CcSEcCtD
Metoclopramide—Agranulocytosis—Methotrexate—breast cancer	0.000112	0.000628	CcSEcCtD
Metoclopramide—Dyspnoea—Paclitaxel—breast cancer	0.000111	0.000626	CcSEcCtD
Metoclopramide—Headache—Thiotepa—breast cancer	0.000111	0.000625	CcSEcCtD
Metoclopramide—Somnolence—Paclitaxel—breast cancer	0.000111	0.000624	CcSEcCtD
Metoclopramide—Palpitations—Capecitabine—breast cancer	0.000111	0.000624	CcSEcCtD
Metoclopramide—Nausea—Vinorelbine—breast cancer	0.00011	0.00062	CcSEcCtD
Metoclopramide—Cisapride—CYP3A4—breast cancer	0.00011	0.0125	CrCbGaD
Metoclopramide—Asthenia—Irinotecan—breast cancer	0.00011	0.000618	CcSEcCtD
Metoclopramide—Asthenia—Mitoxantrone—breast cancer	0.00011	0.000618	CcSEcCtD
Metoclopramide—Jaundice—Epirubicin—breast cancer	0.000109	0.000613	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—breast cancer	0.000109	0.000611	CcSEcCtD
Metoclopramide—Hypertension—Capecitabine—breast cancer	0.000108	0.00061	CcSEcCtD
Metoclopramide—Hypersensitivity—Fluorouracil—breast cancer	0.000108	0.000607	CcSEcCtD
Metoclopramide—Fatigue—Paclitaxel—breast cancer	0.000108	0.000605	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—breast cancer	0.000107	0.000603	CcSEcCtD
Metoclopramide—Asthenia—Gemcitabine—breast cancer	0.000107	0.000602	CcSEcCtD
Metoclopramide—Confusional state—Docetaxel—breast cancer	0.000107	0.0006	CcSEcCtD
Metoclopramide—Anxiety—Capecitabine—breast cancer	0.000107	0.000599	CcSEcCtD
Metoclopramide—Oedema—Docetaxel—breast cancer	0.000106	0.000595	CcSEcCtD
Metoclopramide—Nausea—Thiotepa—breast cancer	0.000105	0.000592	CcSEcCtD
Metoclopramide—Diarrhoea—Mitoxantrone—breast cancer	0.000105	0.000589	CcSEcCtD
Metoclopramide—Diarrhoea—Irinotecan—breast cancer	0.000105	0.000589	CcSEcCtD
Metoclopramide—Agranulocytosis—Epirubicin—breast cancer	0.000105	0.000587	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—breast cancer	0.000104	0.000582	CcSEcCtD
Metoclopramide—Visual impairment—Methotrexate—breast cancer	0.000104	0.000582	CcSEcCtD
Metoclopramide—Confusional state—Capecitabine—breast cancer	0.000103	0.000581	CcSEcCtD
Metoclopramide—Tachycardia—Docetaxel—breast cancer	0.000103	0.000581	CcSEcCtD
Metoclopramide—Feeling abnormal—Paclitaxel—breast cancer	0.000103	0.000579	CcSEcCtD
Metoclopramide—Oedema—Capecitabine—breast cancer	0.000103	0.000576	CcSEcCtD
Metoclopramide—Bradycardia—Epirubicin—breast cancer	0.000102	0.000575	CcSEcCtD
Metoclopramide—Diarrhoea—Gemcitabine—breast cancer	0.000102	0.000574	CcSEcCtD
Metoclopramide—Dizziness—Irinotecan—breast cancer	0.000101	0.000569	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—breast cancer	0.000101	0.000568	CcSEcCtD
Metoclopramide—Diarrhoea—Fluorouracil—breast cancer	0.0001	0.000564	CcSEcCtD
Metoclopramide—Tachycardia—Capecitabine—breast cancer	0.0001	0.000562	CcSEcCtD
Metoclopramide—Urticaria—Paclitaxel—breast cancer	9.93e-05	0.000558	CcSEcCtD
Metoclopramide—Hypotension—Docetaxel—breast cancer	9.9e-05	0.000556	CcSEcCtD
Metoclopramide—Body temperature increased—Paclitaxel—breast cancer	9.88e-05	0.000555	CcSEcCtD
Metoclopramide—Dizziness—Fluorouracil—breast cancer	9.7e-05	0.000545	CcSEcCtD
Metoclopramide—Visual impairment—Epirubicin—breast cancer	9.69e-05	0.000544	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—breast cancer	9.67e-05	0.000543	CcSEcCtD
Metoclopramide—Rash—Irinotecan—breast cancer	9.66e-05	0.000543	CcSEcCtD
Metoclopramide—Rash—Mitoxantrone—breast cancer	9.66e-05	0.000543	CcSEcCtD
Metoclopramide—Dermatitis—Mitoxantrone—breast cancer	9.65e-05	0.000542	CcSEcCtD
Metoclopramide—Dermatitis—Irinotecan—breast cancer	9.65e-05	0.000542	CcSEcCtD
Metoclopramide—Headache—Mitoxantrone—breast cancer	9.6e-05	0.000539	CcSEcCtD
Metoclopramide—Headache—Irinotecan—breast cancer	9.6e-05	0.000539	CcSEcCtD
Metoclopramide—Hypotension—Capecitabine—breast cancer	9.58e-05	0.000538	CcSEcCtD
Metoclopramide—Insomnia—Docetaxel—breast cancer	9.58e-05	0.000538	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—breast cancer	9.47e-05	0.000532	CcSEcCtD
Metoclopramide—Dyspnoea—Docetaxel—breast cancer	9.44e-05	0.000531	CcSEcCtD
Metoclopramide—Somnolence—Docetaxel—breast cancer	9.42e-05	0.000529	CcSEcCtD
Metoclopramide—Rash—Gemcitabine—breast cancer	9.41e-05	0.000529	CcSEcCtD
Metoclopramide—Dermatitis—Gemcitabine—breast cancer	9.4e-05	0.000528	CcSEcCtD
Metoclopramide—Headache—Gemcitabine—breast cancer	9.35e-05	0.000525	CcSEcCtD
Metoclopramide—Flushing—Epirubicin—breast cancer	9.33e-05	0.000524	CcSEcCtD
Metoclopramide—Insomnia—Capecitabine—breast cancer	9.27e-05	0.000521	CcSEcCtD
Metoclopramide—Rash—Fluorouracil—breast cancer	9.25e-05	0.00052	CcSEcCtD
Metoclopramide—Dermatitis—Fluorouracil—breast cancer	9.24e-05	0.000519	CcSEcCtD
Metoclopramide—Hypersensitivity—Paclitaxel—breast cancer	9.21e-05	0.000517	CcSEcCtD
Metoclopramide—Headache—Fluorouracil—breast cancer	9.19e-05	0.000517	CcSEcCtD
Metoclopramide—Dyspnoea—Capecitabine—breast cancer	9.14e-05	0.000514	CcSEcCtD
Metoclopramide—Fatigue—Docetaxel—breast cancer	9.13e-05	0.000513	CcSEcCtD
Metoclopramide—Nausea—Mitoxantrone—breast cancer	9.1e-05	0.000511	CcSEcCtD
Metoclopramide—Nausea—Irinotecan—breast cancer	9.1e-05	0.000511	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—breast cancer	8.97e-05	0.000504	CcSEcCtD
Metoclopramide—Asthenia—Paclitaxel—breast cancer	8.96e-05	0.000504	CcSEcCtD
Metoclopramide—Nausea—Gemcitabine—breast cancer	8.86e-05	0.000498	CcSEcCtD
Metoclopramide—Fatigue—Capecitabine—breast cancer	8.84e-05	0.000497	CcSEcCtD
Metoclopramide—Feeling abnormal—Docetaxel—breast cancer	8.73e-05	0.00049	CcSEcCtD
Metoclopramide—Nausea—Fluorouracil—breast cancer	8.72e-05	0.00049	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—breast cancer	8.63e-05	0.000485	CcSEcCtD
Metoclopramide—Diarrhoea—Paclitaxel—breast cancer	8.55e-05	0.00048	CcSEcCtD
Metoclopramide—Nervousness—Epirubicin—breast cancer	8.5e-05	0.000478	CcSEcCtD
Metoclopramide—Feeling abnormal—Capecitabine—breast cancer	8.45e-05	0.000475	CcSEcCtD
Metoclopramide—Muscle spasms—Epirubicin—breast cancer	8.42e-05	0.000473	CcSEcCtD
Metoclopramide—Body temperature increased—Docetaxel—breast cancer	8.37e-05	0.00047	CcSEcCtD
Metoclopramide—Leukopenia—Methotrexate—breast cancer	8.37e-05	0.00047	CcSEcCtD
Metoclopramide—Dizziness—Paclitaxel—breast cancer	8.26e-05	0.000464	CcSEcCtD
Metoclopramide—Urticaria—Capecitabine—breast cancer	8.15e-05	0.000458	CcSEcCtD
Metoclopramide—Body temperature increased—Capecitabine—breast cancer	8.11e-05	0.000455	CcSEcCtD
Metoclopramide—Convulsion—Methotrexate—breast cancer	8.1e-05	0.000455	CcSEcCtD
Metoclopramide—Agitation—Epirubicin—breast cancer	8.04e-05	0.000452	CcSEcCtD
Metoclopramide—Rash—Paclitaxel—breast cancer	7.88e-05	0.000443	CcSEcCtD
Metoclopramide—Dermatitis—Paclitaxel—breast cancer	7.87e-05	0.000442	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—breast cancer	7.87e-05	0.000442	CcSEcCtD
Metoclopramide—Leukopenia—Epirubicin—breast cancer	7.83e-05	0.00044	CcSEcCtD
Metoclopramide—Headache—Paclitaxel—breast cancer	7.83e-05	0.00044	CcSEcCtD
Metoclopramide—Hypersensitivity—Docetaxel—breast cancer	7.8e-05	0.000438	CcSEcCtD
Metoclopramide—Muscle spasms—Doxorubicin—breast cancer	7.79e-05	0.000438	CcSEcCtD
Metoclopramide—Palpitations—Epirubicin—breast cancer	7.73e-05	0.000435	CcSEcCtD
Metoclopramide—Confusional state—Methotrexate—breast cancer	7.7e-05	0.000432	CcSEcCtD
Metoclopramide—Asthenia—Docetaxel—breast cancer	7.6e-05	0.000427	CcSEcCtD
Metoclopramide—Convulsion—Epirubicin—breast cancer	7.58e-05	0.000426	CcSEcCtD
Metoclopramide—Hypertension—Epirubicin—breast cancer	7.56e-05	0.000425	CcSEcCtD
Metoclopramide—Hypersensitivity—Capecitabine—breast cancer	7.55e-05	0.000424	CcSEcCtD
Metoclopramide—Procainamide—CYP2D6—breast cancer	7.46e-05	0.00843	CrCbGaD
Metoclopramide—Agitation—Doxorubicin—breast cancer	7.44e-05	0.000418	CcSEcCtD
Metoclopramide—Anxiety—Epirubicin—breast cancer	7.43e-05	0.000417	CcSEcCtD
Metoclopramide—Nausea—Paclitaxel—breast cancer	7.42e-05	0.000417	CcSEcCtD
Metoclopramide—Asthenia—Capecitabine—breast cancer	7.36e-05	0.000413	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—breast cancer	7.25e-05	0.000407	CcSEcCtD
Metoclopramide—Diarrhoea—Docetaxel—breast cancer	7.25e-05	0.000407	CcSEcCtD
Metoclopramide—Confusional state—Epirubicin—breast cancer	7.2e-05	0.000405	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—breast cancer	7.16e-05	0.000402	CcSEcCtD
Metoclopramide—Oedema—Epirubicin—breast cancer	7.14e-05	0.000401	CcSEcCtD
Metoclopramide—Hypotension—Methotrexate—breast cancer	7.13e-05	0.000401	CcSEcCtD
Metoclopramide—Convulsion—Doxorubicin—breast cancer	7.02e-05	0.000394	CcSEcCtD
Metoclopramide—Diarrhoea—Capecitabine—breast cancer	7.02e-05	0.000394	CcSEcCtD
Metoclopramide—Dizziness—Docetaxel—breast cancer	7e-05	0.000394	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—breast cancer	6.99e-05	0.000393	CcSEcCtD
Metoclopramide—Tachycardia—Epirubicin—breast cancer	6.97e-05	0.000392	CcSEcCtD
Metoclopramide—Insomnia—Methotrexate—breast cancer	6.9e-05	0.000388	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—breast cancer	6.87e-05	0.000386	CcSEcCtD
Metoclopramide—Dyspnoea—Methotrexate—breast cancer	6.81e-05	0.000382	CcSEcCtD
Metoclopramide—Somnolence—Methotrexate—breast cancer	6.79e-05	0.000381	CcSEcCtD
Metoclopramide—Dizziness—Capecitabine—breast cancer	6.78e-05	0.000381	CcSEcCtD
Metoclopramide—Rash—Docetaxel—breast cancer	6.68e-05	0.000375	CcSEcCtD
Metoclopramide—Hypotension—Epirubicin—breast cancer	6.67e-05	0.000375	CcSEcCtD
Metoclopramide—Dermatitis—Docetaxel—breast cancer	6.67e-05	0.000375	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—breast cancer	6.66e-05	0.000374	CcSEcCtD
Metoclopramide—Headache—Docetaxel—breast cancer	6.63e-05	0.000373	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—breast cancer	6.61e-05	0.000371	CcSEcCtD
Metoclopramide—Fatigue—Methotrexate—breast cancer	6.58e-05	0.00037	CcSEcCtD
Metoclopramide—Sunitinib—CYP3A4—breast cancer	6.55e-05	0.0074	CrCbGaD
Metoclopramide—Rash—Capecitabine—breast cancer	6.47e-05	0.000363	CcSEcCtD
Metoclopramide—Insomnia—Epirubicin—breast cancer	6.46e-05	0.000363	CcSEcCtD
Metoclopramide—Dermatitis—Capecitabine—breast cancer	6.46e-05	0.000363	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—breast cancer	6.45e-05	0.000362	CcSEcCtD
Metoclopramide—Headache—Capecitabine—breast cancer	6.42e-05	0.000361	CcSEcCtD
Metoclopramide—Dyspnoea—Epirubicin—breast cancer	6.37e-05	0.000358	CcSEcCtD
Metoclopramide—Somnolence—Epirubicin—breast cancer	6.35e-05	0.000357	CcSEcCtD
Metoclopramide—Nausea—Docetaxel—breast cancer	6.29e-05	0.000353	CcSEcCtD
Metoclopramide—Feeling abnormal—Methotrexate—breast cancer	6.29e-05	0.000353	CcSEcCtD
Metoclopramide—Hypotension—Doxorubicin—breast cancer	6.18e-05	0.000347	CcSEcCtD
Metoclopramide—Fatigue—Epirubicin—breast cancer	6.16e-05	0.000346	CcSEcCtD
Metoclopramide—Nausea—Capecitabine—breast cancer	6.09e-05	0.000342	CcSEcCtD
Metoclopramide—Urticaria—Methotrexate—breast cancer	6.06e-05	0.000341	CcSEcCtD
Metoclopramide—Body temperature increased—Methotrexate—breast cancer	6.03e-05	0.000339	CcSEcCtD
Metoclopramide—Insomnia—Doxorubicin—breast cancer	5.98e-05	0.000336	CcSEcCtD
Metoclopramide—Dyspnoea—Doxorubicin—breast cancer	5.89e-05	0.000331	CcSEcCtD
Metoclopramide—Feeling abnormal—Epirubicin—breast cancer	5.89e-05	0.000331	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—breast cancer	5.88e-05	0.00033	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—breast cancer	5.7e-05	0.00032	CcSEcCtD
Metoclopramide—Urticaria—Epirubicin—breast cancer	5.67e-05	0.000319	CcSEcCtD
Metoclopramide—Body temperature increased—Epirubicin—breast cancer	5.65e-05	0.000317	CcSEcCtD
Metoclopramide—Hypersensitivity—Methotrexate—breast cancer	5.62e-05	0.000316	CcSEcCtD
Metoclopramide—Asthenia—Methotrexate—breast cancer	5.48e-05	0.000308	CcSEcCtD
Metoclopramide—Sunitinib—ABCB1—breast cancer	5.45e-05	0.00616	CrCbGaD
Metoclopramide—Feeling abnormal—Doxorubicin—breast cancer	5.45e-05	0.000306	CcSEcCtD
Metoclopramide—Hypersensitivity—Epirubicin—breast cancer	5.26e-05	0.000296	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—breast cancer	5.25e-05	0.000295	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—breast cancer	5.23e-05	0.000294	CcSEcCtD
Metoclopramide—Diarrhoea—Methotrexate—breast cancer	5.22e-05	0.000293	CcSEcCtD
Metoclopramide—Asthenia—Epirubicin—breast cancer	5.13e-05	0.000288	CcSEcCtD
Metoclopramide—Dizziness—Methotrexate—breast cancer	5.05e-05	0.000284	CcSEcCtD
Metoclopramide—Diarrhoea—Epirubicin—breast cancer	4.89e-05	0.000275	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—breast cancer	4.87e-05	0.000274	CcSEcCtD
Metoclopramide—Rash—Methotrexate—breast cancer	4.81e-05	0.00027	CcSEcCtD
Metoclopramide—Dermatitis—Methotrexate—breast cancer	4.81e-05	0.00027	CcSEcCtD
Metoclopramide—Headache—Methotrexate—breast cancer	4.78e-05	0.000269	CcSEcCtD
Metoclopramide—Asthenia—Doxorubicin—breast cancer	4.74e-05	0.000266	CcSEcCtD
Metoclopramide—Dizziness—Epirubicin—breast cancer	4.72e-05	0.000265	CcSEcCtD
Metoclopramide—Nausea—Methotrexate—breast cancer	4.53e-05	0.000255	CcSEcCtD
Metoclopramide—Diarrhoea—Doxorubicin—breast cancer	4.52e-05	0.000254	CcSEcCtD
Metoclopramide—Rash—Epirubicin—breast cancer	4.5e-05	0.000253	CcSEcCtD
Metoclopramide—Dermatitis—Epirubicin—breast cancer	4.5e-05	0.000253	CcSEcCtD
Metoclopramide—Headache—Epirubicin—breast cancer	4.48e-05	0.000251	CcSEcCtD
Metoclopramide—Dizziness—Doxorubicin—breast cancer	4.37e-05	0.000246	CcSEcCtD
Metoclopramide—Nausea—Epirubicin—breast cancer	4.24e-05	0.000238	CcSEcCtD
Metoclopramide—Rash—Doxorubicin—breast cancer	4.17e-05	0.000234	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—breast cancer	4.16e-05	0.000234	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—breast cancer	4.14e-05	0.000233	CcSEcCtD
Metoclopramide—Nausea—Doxorubicin—breast cancer	3.93e-05	0.000221	CcSEcCtD
Metoclopramide—CYP2D6—Metabolism—ENO1—breast cancer	6.55e-06	4.67e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS1—breast cancer	6.55e-06	4.67e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1R—breast cancer	6.54e-06	4.66e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL8—breast cancer	6.51e-06	4.64e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—breast cancer	6.47e-06	4.62e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FN1—breast cancer	6.47e-06	4.62e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SMAD4—breast cancer	6.44e-06	4.59e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HES1—breast cancer	6.42e-06	4.58e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1R—breast cancer	6.4e-06	4.56e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NFKBIA—breast cancer	6.4e-06	4.56e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NCOR1—breast cancer	6.38e-06	4.55e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PLA2G4A—breast cancer	6.38e-06	4.55e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL8—breast cancer	6.37e-06	4.54e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NOTCH1—breast cancer	6.34e-06	4.52e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CSF2—breast cancer	6.31e-06	4.5e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGF1—breast cancer	6.31e-06	4.5e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NCOA2—breast cancer	6.31e-06	4.5e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—RAF1—breast cancer	6.3e-06	4.49e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HES1—breast cancer	6.28e-06	4.48e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NRG1—breast cancer	6.27e-06	4.47e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PLA2G4A—breast cancer	6.25e-06	4.46e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NCOR1—breast cancer	6.25e-06	4.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—H2AFX—breast cancer	6.22e-06	4.44e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—IL2—breast cancer	6.22e-06	4.44e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KIT—breast cancer	6.2e-06	4.42e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CG—breast cancer	6.2e-06	4.42e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APC—breast cancer	6.2e-06	4.42e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGF1—breast cancer	6.18e-06	4.41e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CSF2—breast cancer	6.18e-06	4.41e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—E2F1—breast cancer	6.18e-06	4.41e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—RAF1—breast cancer	6.16e-06	4.4e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CB—breast cancer	6.15e-06	4.39e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NRG1—breast cancer	6.13e-06	4.38e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGF—breast cancer	6.12e-06	4.37e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—FASN—breast cancer	6.12e-06	4.36e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CA—breast cancer	6.11e-06	4.36e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—BCHE—breast cancer	6.09e-06	4.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—H2AFX—breast cancer	6.09e-06	4.34e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—IL2—breast cancer	6.09e-06	4.34e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—E2F1—breast cancer	6.05e-06	4.31e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CB—breast cancer	6.02e-06	4.29e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC5A5—breast cancer	6.02e-06	4.29e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SPP1—breast cancer	5.94e-06	4.23e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK3—breast cancer	5.93e-06	4.23e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL8—breast cancer	5.91e-06	4.22e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB3—breast cancer	5.87e-06	4.19e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGFR2—breast cancer	5.86e-06	4.18e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—BRAF—breast cancer	5.82e-06	4.15e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NQO1—breast cancer	5.81e-06	4.15e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC2A1—breast cancer	5.81e-06	4.15e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SPP1—breast cancer	5.81e-06	4.14e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—breast cancer	5.79e-06	4.13e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL8—breast cancer	5.78e-06	4.13e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB3—breast cancer	5.75e-06	4.1e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGFR2—breast cancer	5.74e-06	4.09e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CA—breast cancer	5.71e-06	4.08e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1—breast cancer	5.67e-06	4.05e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT2—breast cancer	5.67e-06	4.04e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP3A4—breast cancer	5.67e-06	4.04e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL2—breast cancer	5.65e-06	4.03e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—EGFR—breast cancer	5.64e-06	4.03e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TERT—breast cancer	5.63e-06	4.01e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP1B1—breast cancer	5.57e-06	3.97e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL2—breast cancer	5.53e-06	3.94e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TERT—breast cancer	5.51e-06	3.93e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HSP90AA1—breast cancer	5.46e-06	3.9e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGFR1—breast cancer	5.46e-06	3.9e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CD—breast cancer	5.45e-06	3.89e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CA—breast cancer	5.39e-06	3.85e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SERPINE1—breast cancer	5.39e-06	3.84e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HIF1A—breast cancer	5.38e-06	3.84e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGFR1—breast cancer	5.35e-06	3.81e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KRAS—breast cancer	5.33e-06	3.8e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NCOA1—breast cancer	5.32e-06	3.79e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HIF1A—breast cancer	5.27e-06	3.76e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LEP—breast cancer	5.25e-06	3.75e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—STK11—breast cancer	5.24e-06	3.74e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP19A1—breast cancer	5.24e-06	3.74e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CAV1—breast cancer	5.2e-06	3.71e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KDR—breast cancer	5.15e-06	3.67e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NOS3—breast cancer	5.14e-06	3.67e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LEP—breast cancer	5.14e-06	3.67e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CAV1—breast cancer	5.09e-06	3.63e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KDR—breast cancer	5.04e-06	3.59e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ESR1—breast cancer	5.02e-06	3.58e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—breast cancer	4.99e-06	3.56e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FN1—breast cancer	4.95e-06	3.53e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ESR1—breast cancer	4.91e-06	3.5e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CA—breast cancer	4.9e-06	3.5e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NFKBIA—breast cancer	4.9e-06	3.49e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MDM2—breast cancer	4.88e-06	3.48e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—COMT—breast cancer	4.87e-06	3.47e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RAF1—breast cancer	4.86e-06	3.47e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FN1—breast cancer	4.85e-06	3.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOTCH1—breast cancer	4.85e-06	3.46e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTP1—breast cancer	4.85e-06	3.46e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RELA—breast cancer	4.84e-06	3.45e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB2—breast cancer	4.81e-06	3.43e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NFKBIA—breast cancer	4.79e-06	3.42e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HMOX1—breast cancer	4.78e-06	3.41e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ITPR1—breast cancer	4.77e-06	3.4e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CB—breast cancer	4.75e-06	3.39e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MTOR—breast cancer	4.75e-06	3.39e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOTCH1—breast cancer	4.74e-06	3.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APC—breast cancer	4.74e-06	3.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KIT—breast cancer	4.74e-06	3.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CG—breast cancer	4.74e-06	3.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGF—breast cancer	4.69e-06	3.34e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—breast cancer	4.67e-06	3.33e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CG—breast cancer	4.64e-06	3.31e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APC—breast cancer	4.64e-06	3.31e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KIT—breast cancer	4.64e-06	3.31e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ABCB1—breast cancer	4.59e-06	3.27e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGF—breast cancer	4.59e-06	3.27e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL8—breast cancer	4.56e-06	3.25e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK3—breast cancer	4.54e-06	3.24e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRAS—breast cancer	4.53e-06	3.23e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMS—breast cancer	4.51e-06	3.21e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—BRAF—breast cancer	4.46e-06	3.18e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1B—breast cancer	4.46e-06	3.18e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PLA2G4A—breast cancer	4.45e-06	3.18e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NCOR1—breast cancer	4.45e-06	3.18e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTM1—breast cancer	4.45e-06	3.18e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK3—breast cancer	4.44e-06	3.17e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—breast cancer	4.41e-06	3.14e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CASP3—breast cancer	4.37e-06	3.12e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—BRAF—breast cancer	4.36e-06	3.11e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL2—breast cancer	4.36e-06	3.11e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1—breast cancer	4.34e-06	3.1e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—breast cancer	4.34e-06	3.09e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT2—breast cancer	4.34e-06	3.09e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EGFR—breast cancer	4.32e-06	3.08e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GPX1—breast cancer	4.27e-06	3.04e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCND1—breast cancer	4.25e-06	3.03e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1—breast cancer	4.25e-06	3.03e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT2—breast cancer	4.25e-06	3.03e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—JUN—breast cancer	4.24e-06	3.03e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EGFR—breast cancer	4.23e-06	3.02e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP1A1—breast cancer	4.22e-06	3.01e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CTNNB1—breast cancer	4.21e-06	3e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ERCC2—breast cancer	4.19e-06	2.99e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CD—breast cancer	4.17e-06	2.97e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CA—breast cancer	4.13e-06	2.95e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—breast cancer	4.13e-06	2.94e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SERPINE1—breast cancer	4.12e-06	2.94e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1A—breast cancer	4.11e-06	2.93e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTEN—breast cancer	4.1e-06	2.93e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KRAS—breast cancer	4.08e-06	2.91e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CD—breast cancer	4.08e-06	2.91e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	4.04e-06	2.88e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SERPINE1—breast cancer	4.03e-06	2.88e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK8—breast cancer	4.01e-06	2.86e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—breast cancer	4e-06	2.86e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KRAS—breast cancer	3.99e-06	2.85e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MTHFR—breast cancer	3.94e-06	2.81e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOS3—breast cancer	3.94e-06	2.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOS3—breast cancer	3.85e-06	2.75e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SRC—breast cancer	3.8e-06	2.71e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CA—breast cancer	3.75e-06	2.67e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MDM2—breast cancer	3.73e-06	2.66e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RAF1—breast cancer	3.72e-06	2.65e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—breast cancer	3.71e-06	2.64e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RELA—breast cancer	3.7e-06	2.64e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB2—breast cancer	3.68e-06	2.63e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT3—breast cancer	3.67e-06	2.62e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	3.67e-06	2.62e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MDM2—breast cancer	3.65e-06	2.61e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RAF1—breast cancer	3.64e-06	2.6e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MTOR—breast cancer	3.63e-06	2.59e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CB—breast cancer	3.63e-06	2.59e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CAV1—breast cancer	3.63e-06	2.59e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RELA—breast cancer	3.63e-06	2.59e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB2—breast cancer	3.6e-06	2.57e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CB—breast cancer	3.56e-06	2.54e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MTOR—breast cancer	3.56e-06	2.54e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK3—breast cancer	3.51e-06	2.5e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL8—breast cancer	3.49e-06	2.49e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRAS—breast cancer	3.47e-06	2.47e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL8—breast cancer	3.42e-06	2.44e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1B—breast cancer	3.41e-06	2.43e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—breast cancer	3.41e-06	2.43e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TGFB1—breast cancer	3.4e-06	2.43e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRAS—breast cancer	3.39e-06	2.42e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—breast cancer	3.37e-06	2.41e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CASP3—breast cancer	3.34e-06	2.38e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1B—breast cancer	3.34e-06	2.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL2—breast cancer	3.34e-06	2.38e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGFR—breast cancer	3.33e-06	2.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—breast cancer	3.32e-06	2.37e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CG—breast cancer	3.31e-06	2.36e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—breast cancer	3.3e-06	2.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CASP3—breast cancer	3.27e-06	2.33e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL2—breast cancer	3.27e-06	2.33e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCND1—breast cancer	3.25e-06	2.32e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—breast cancer	3.25e-06	2.32e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—JUN—breast cancer	3.25e-06	2.32e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CTNNB1—breast cancer	3.22e-06	2.3e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCND1—breast cancer	3.18e-06	2.27e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JUN—breast cancer	3.18e-06	2.27e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—breast cancer	3.16e-06	2.25e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CTNNB1—breast cancer	3.15e-06	2.25e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KRAS—breast cancer	3.15e-06	2.25e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1A—breast cancer	3.15e-06	2.24e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTEN—breast cancer	3.14e-06	2.24e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—breast cancer	3.09e-06	2.2e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1A—breast cancer	3.08e-06	2.2e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTEN—breast cancer	3.07e-06	2.19e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK8—breast cancer	3.07e-06	2.19e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—breast cancer	3.06e-06	2.18e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK8—breast cancer	3.01e-06	2.14e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—breast cancer	3e-06	2.14e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SRC—breast cancer	2.91e-06	2.08e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CD—breast cancer	2.91e-06	2.07e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CA—breast cancer	2.89e-06	2.06e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALB—breast cancer	2.87e-06	2.05e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SRC—breast cancer	2.85e-06	2.03e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—breast cancer	2.84e-06	2.02e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT3—breast cancer	2.81e-06	2e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—breast cancer	2.8e-06	2e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—breast cancer	2.77e-06	1.98e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT3—breast cancer	2.75e-06	1.96e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NOS3—breast cancer	2.75e-06	1.96e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK3—breast cancer	2.68e-06	1.91e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRAS—breast cancer	2.68e-06	1.91e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK3—breast cancer	2.62e-06	1.87e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—breast cancer	2.61e-06	1.86e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TGFB1—breast cancer	2.6e-06	1.86e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—breast cancer	2.56e-06	1.83e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—breast cancer	2.55e-06	1.82e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGFR—breast cancer	2.55e-06	1.82e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TGFB1—breast cancer	2.55e-06	1.82e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CB—breast cancer	2.53e-06	1.81e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—breast cancer	2.51e-06	1.79e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGFR—breast cancer	2.5e-06	1.78e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KRAS—breast cancer	2.41e-06	1.72e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—breast cancer	2.36e-06	1.69e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KRAS—breast cancer	2.36e-06	1.68e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CA—breast cancer	2.21e-06	1.58e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTEN—breast cancer	2.19e-06	1.56e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CA—breast cancer	2.17e-06	1.55e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—breast cancer	2.14e-06	1.53e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—breast cancer	2.1e-06	1.5e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRAS—breast cancer	2.05e-06	1.46e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRAS—breast cancer	2.01e-06	1.43e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—breast cancer	1.96e-06	1.4e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—breast cancer	1.92e-06	1.37e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—breast cancer	1.81e-06	1.29e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—breast cancer	1.77e-06	1.26e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CA—breast cancer	1.54e-06	1.1e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—breast cancer	1.26e-06	9e-06	CbGpPWpGaD
